Mr. Guangming Lin comes from a background in biomaterials and medical technology. After graduating from Nanjing Tech University with a degree in Biochemical Engineering, he further specialized in peptide synthesis and biomedical material research. He later held key positions at internationally recognized medical device companies including Johnson & Johnson, Stryker, Zimmer Biomet, and WEGO. Through years of industry experience, he developed a deep understanding of the relationship between material innovation and clinical needs, gradually shaping his long-term vision for regenerative aesthetics.
During this period, he also participated in China’s National “863 Program” related to absorbable biomaterials, contributing to the industrialization of regenerative medical materials. Through nearly two decades of industry experience, research, and clinical observation, he gradually formed a long-term vision for regenerative aesthetics — one grounded in science, safety, and respect for natural beauty.
Guangming Lin, Founder of Moyom Biotech and the Visionary Behind Aphranel
A Commitment to Time and Long-Termism
Everything began with a belief: Regenerative aesthetics should not be driven by short-term trends, age anxiety, or immediate results. Instead, it should be grounded in science, safety, and long-term value.
Founded by Mr. Guangming Lin after more than a decade of research into CaHA biomaterials, Aphranel was created with a philosophy of “Be with time”, redefining the relationship between regenerative aesthetics and beauty.
Mr. Guangming Lin comes from a background in biomaterials and medical technology. After graduating from Nanjing Tech University with a degree in Biochemical Engineering, he further specialized in peptide synthesis and biomedical material research. He later held key positions at internationally recognized medical device companies including Johnson & Johnson, Stryker, Zimmer Biomet, and WEGO. Through years of industry experience, he developed a deep understanding of the relationship between material innovation and clinical needs, gradually shaping his long-term vision for regenerative aesthetics.
During this period, he also participated in China’s National “863 Program” related to absorbable biomaterials, contributing to the industrialization of regenerative medical materials. Through nearly two decades of industry experience, research, and clinical observation, he gradually formed a long-term vision for regenerative aesthetics — one grounded in science, safety, and respect for natural beauty.
During this period, he also participated in China’s National “863 Program” related to absorbable biomaterials, contributing to the industrialization of regenerative medical materials. Through nearly two decades of industry experience, research, and clinical observation, he gradually formed a long-term vision for regenerative aesthetics — one grounded in science, safety, and respect for natural beauty.
In 2016, Mr. Guangming Lin collaborated with leading Chinese research institutions on the National Key R&D Program for Biomedical Materials and Tissue Regeneration. Driven by a deep belief in the long-term value of regenerative aesthetics, he and his team devoted 12 years to the study of CaHA materials — continuously researching microsphere structures, degradation behavior, and regenerative mechanisms. From in-vitro degradation studies and animal testing to long-term clinical validation, every step was guided by scientific rigor and long-term safety.
For Mr. Lin, scientific innovation is never about short-term trends, but about patience, safety, and long-term value. In 2018, Moyom Biotechnology was officially established, marking a significant milestone in the transition of CaHA regenerative materials from foundational research to industrialized development.
For Mr. Lin, scientific innovation is never about short-term trends, but about patience, safety, and long-term value. In 2018, Moyom Biotechnology was officially established, marking a significant milestone in the transition of CaHA regenerative materials from foundational research to industrialized development.
In 2016, Mr. Guangming Lin collaborated with leading Chinese research institutions on the National Key R&D Program for Biomedical Materials and Tissue Regeneration. Driven by a deep belief in the long-term value of regenerative aesthetics, he and his team devoted 12 years to the study of CaHA materials — continuously researching microsphere structures, degradation behavior, and regenerative mechanisms. From in-vitro degradation studies and animal testing to long-term clinical validation, every step was guided by scientific rigor and long-term safety.
For Mr. Lin, scientific innovation is never about short-term trends, but about patience, safety, and long-term value. In 2018, Moyom Biotechnology was officially established, marking a significant milestone in the transition of CaHA regenerative materials from foundational research to industrialized development.
For Mr. Lin, scientific innovation is never about short-term trends, but about patience, safety, and long-term value. In 2018, Moyom Biotechnology was officially established, marking a significant milestone in the transition of CaHA regenerative materials from foundational research to industrialized development.
Guangming Lin
Founder of Aphranel
We have always believed that true beauty should never come from fighting against time. Regenerative aesthetics should respect the natural rhythm of life, allowing people to age naturally, confidently, and gracefully. Through science and regenerative medicine, we are committed to creating long-term value for doctors, customers, and the future of regenerative aesthetics.
Aphranel has obtained China NMPA Class III Medical Device Certification in 2025, along with multiple international certifications, and delivered over 150,000 syringes worldwide within its first year.
With collaborations across x'x'x medical institutions and clinics worldwide, Aphranel continues to advance regenerative aesthetics through science, structure, and long-term innovation.
Guangming Lin
Founder of Aphranel
Create exceptional products. Advance clinical understanding through science and education. Deliver genuine value to consumers. Whether it takes three years, five years, or even ten years, we are committed to building a truly world-class regenerative aesthetics brand from China. That is Aphranel’s conviction, and ultimately, time will provide the answer.
Keep reading
Page
Global Certifications
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Page
Company News (Media Coverage)
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX